Completion of the book-building process for the offering of new series T bearer shares and determination of the issue price for series T shares

Current report no. 37/2024

Drafting date: 22 November 2024

Subject: Completion of the book-building process for the offering of new series T bearer shares and determination of the issue price for series T shares

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław, the ‘Issuer’ or the
‘Company’, with reference to current report No. 35/2024 of 20 November 2024 and current report No. 36/2024 of 20 November 2024, announces that on 22 November 2024,  was completed, conducted by Trigon Dom Maklerski S.A., Trigon Investment Banking spółka z ograniczoną odpowiedzialnością & Wspólnicy sp. k. and mBank S.A, conducting brokerage activities within the framework of a separate organisational unit - a brokerage office using the name of Biuro Maklerskie mBank (‘Investment Companies’), the book-building process for up to 822,467 series T ordinary bearer shares of the Company (‘Series T Shares’) issued pursuant to the Management Board's Resolution No. 2 of 20 November 2024 on increasing the Company's share capital within the limits of the authorised capital through the issue of series T shares, with the exclusion of pre-emptive rights and on amending §6(1) of the Company's Articles of Association.

Accordingly, on 22 November 2024, after considering the results of the book-building process and the recommendations of the Investment Companies, the Management Board of the Company, having obtained the approval of the Supervisory Board of the Company, determined the final issue price of the Series T Shares to be PLN 40.00 (forty zlotys) per Series T Share and decided to make offers to investors to acquire Series T Shares at the determined issue price in relation to all 822,467 (eight hundred and twenty-two thousand four hundred and sixty-seven) Series T Shares. At the same time, the Company and the Investment Companies entered into a price annex to the Share Placement Agreement confirming the above arrangements and determining the initial allocation of the Series T Shares.

ADDITIONAL INFORMATION

This current report has been prepared solely for the purpose of fulfilling the obligations arising from Article 17(1) of Regulation EU No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse Regulation and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC MAR, as the Company considered the information on the commencement of the Accelerated Book-building Process for Series T Shares as meeting the criteria of confidential information within the meaning of Article 7 MAR. This report is in no way intended to promote, directly or indirectly, the offer, subscription or purchase of the Series T Shares and does not constitute advertising or promotional material prepared or published by the Company for the purpose of promoting the Offering of the Series T Shares or to encourage investors, directly or indirectly, to purchase or subscribe for the Series T Shares.